Business Daily from THE HINDU group of publications
Wednesday, May 30, 2007
ePaper
Business Daily from THE HINDU group of publications Wednesday, May 30, 2007 ePaper |
|
|
|
|
|
|
|
Corporate
-
Outlook Eli Lilly working on diabetes injectible drug Our Bureau
Mumbai May 29 Eli Lilly is in the process of submitting documents to the Drug-Controller General of India on Byetta, an injectible medicine for people with type II diabetes. Stating that the company was filing the documents with the regulatory agency, Mr Sandeep Gupta, Chairman and Managing Director of Eli Lilly in India, said that the company is keen on launching the product at the earliest opportunity. Byetta (exenatide) belongs to a new class of diabetes medicines used to improve glucose or blood sugar control in adults. It was recently launched in parts of Europe. Sold under the brand name Byetta, it was approved for sale in the US in April 2005.
Market scope
The anti-diabetes market in India is estimated to be worth Rs 1,400 crore, with insulin accounting for about Rs 350 crore. Apart from diabetes, Eli Lilly is interested in bringing new products in other segments such as therapeutic areas including oncology and women's health, Mr Gupta said.
Cancer drug
Late last year, the company had launched Alimta, used in treating a rare type of cancer. It also has an approved second line of treatment for non small-cell lung cancer. The drug was approved in 2004 in the US.
Cialis
However, the company's optimism on bringing new products into India has seen a dampener in its plans to launch Cialis or tadalafil for erectile dysfunction being shelved. In the same league as Pfizer's Viagra, Cialis too had to face an onslaught of generic copies made locally.
Generic copies
And though Pfizer relented and eventually launched Viagra in India, Eli Lilly top brass confirmed that the company has indeed shelved its plans to launch Cialis in India. The drug had been slated for a launch in 2004, but subsequently got embroiled in patent-related cases with Ajanta Pharma and Ranbaxy, both producers of generic copies of tadalafil.
More Stories on : Outlook | Regulatory Bodies & Rulings | Pharmaceuticals
Article E-Mail :: Comment :: Syndication :: Printer Friendly Page
|
Stories in this Section |
|
The Hindu Group: Home | About Us | Copyright | Archives | Contacts | Subscription Group Sites: The Hindu | The Hindu ePaper | Business Line | Business Line ePaper | Sportstar | Frontline | The Hindu eBooks | The Hindu Images | Home |
Copyright © 2007, The
Hindu Business Line. Republication or redissemination of the contents of
this screen are expressly prohibited without the written consent of
The Hindu Business Line
|